Nebivolol Versus Carvedilol in Patients With Heart Failure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00511888|
Recruitment Status : Terminated (is finish)
First Posted : August 6, 2007
Last Update Posted : October 17, 2008
BACKGROUND Beta-blockers improve left ventricular (LV) systolic function and prognosis in patients with chronic heart failure. Both carvedilol and nebivolol have hemodynamic and clinical benefits in chronic heart failure (CHF), but it is unknown whether their pleiotropic properties may play a role in different subgroups of patients with CHF.
OBJECTIVE: To compare the effects of nebivolol and carvedilol on LV function and clinical outcome in patients with chronic heart failure and reduced LV systolic function.
METHODS: 160 hypertensive CHF patients, LV ejection fraction (EF) 40% and in New York Heart Association (NYHA) functional class II or III were randomly assigned to receive carvedilol or nebivolol therapy for 24 months. At baseline and after 24 months of treatment, all patients underwent clinical evaluation: echocardiogram and 6-minute walking test.
|Condition or disease|
|Chronic Heart Failure Hypertension|
|Study Type :||Observational|
|Actual Enrollment :||160 participants|
|Official Title:||Effects of Nebivolol Versus Carvedilol in Hypertensive Patients With Chronic Heart Failure|
|Study Start Date :||January 2004|
|Actual Study Completion Date :||June 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00511888
|IRCCS San Raffaele|
|Rome, Italy, 00163|
|Study Director:||giuseppe rosano, md||IRCCS san Raffaele Cardiovascular Research Unit|